Device and method for restoration of the condition of blood

• US 8,663,148 B2
• Filed: 06/18/2008
• Issued: 03/04/2014
• Est. Priority Date: 06/18/2007
• Status: Active Grant

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: Larm, Olle, Axelsson, Jonas, Adolfsson, Lars, Ward, Robert S., McCrea, Keith, Bergstrm, Tomas
• Primary Examiner(s): Shen, Wu-Cheng Winston
• Assistant Examiner(s): Shiao, Yih-Horng
• Application Number:
  US12/665,156
• Publication Number:
  US 20100249689A1
• Time in Patent Office: 2,085 Days
• Field of Search: 604/5.04, 536/21
• US Class Current: 604/5.04
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: B01J 20/3272 Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
• CPC Class Codes: B01J 20/3274 Proteins, nucleic acids, polysaccharides, antibodies or antigens
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a device for extracorporeal removal of harmful agents from blood or blood components, comprising full length heparin immobilized on a solid substrate by covalent end point attachment. The present invention also relates to a method for extracorporeal removal of a harmful agent from mammalian blood or blood components. The present invention further relates to a process for covalent end point attachment of full length heparin to a solid substrate.

Claims

1. A device for extracorporeal removal of a harmful agent having a binding affinity to heparin from blood or blood components, the device comprising a full length heparin immobilized on a solid substrate by a covalent end point attachment, where said covalent end point attachment is formed by a process comprising the steps of:

a) providing said solid substrate having primary amino functional groups,

b) mixing said solid substrate of a) with said full length heparin and a reducing agent in an aqueous medium,

c) allowing said full length heparin to bind covalently to the amino functional groups, wherein the covalent binding reaction between said full length heparin and the amino groups is performed at 60°

C., and

d) recovering the solid substrate having said full length heparin covalently bound on its surface.

2. The device according to claim 1, wherein said full length heparin has a mean molecular weight in the range of 15-25 kDa.

3. The device according to claim 1, wherein said full length heparin has a mean molecular weight of more than 21 kDa.

4. The device according to claim 1, wherein the a surface concentration of said full length heparin is 1-20 μ

g/cm².

5. The device according to claim 1, wherein a surface concentration of said full length heparin is 5-15 μ

g/cm².

6. The device according to claim 1, wherein said full length heparin is covalently attached to said solid substrate via stable secondary amino groups.

7. The device according to claim 1, wherein a total surface area of said solid substrate is in the range of 0.5-3 m².

8. The device according to claim 1, wherein said solid substrate comprises a particle or a bead.

9. The device according to claim 8, wherein a diameter of the particle or the bead is in the range of 10-1,000 μ

m.

10. The device according to claim 9, wherein the diameter of the particle or the bead is in the range of 20-200 μ

m.

11. The device according to claim 8, wherein said particle or said bead comprises a material selected from the group consisting of polyurethanes, polyolefins, silicones, fluoropolymers, poly(methyl methacrylate), glass, cross linked alginates, and cross linked polysaccharides, wherein the cross linked polysaccharide are selected from the group consisting of agarose, dextran, cellulose, chitosan and starch.

12. The device according to claim 1, wherein said solid substrate comprises one or more hollow fibers.

13. The device according to claim 12, wherein an inner diameter of said hollow fiber is in the range of 10-1,000 μ

m.

14. The device according to claim 13, wherein the inner diameter of said hollow fiber is in the range of 20-200 μ

m.

15. The device according to claim 12, wherein said hollow fiber comprises a material selected from the group consisting of polysulfones, polyamides, polynitriles, polypropylenes, cross linked alginates, and cellulose.

16. The device according to claim 1, wherein the device is a column comprising a casing containing the full length heparin immobilized on the solid substrate, said column having an inlet through which blood enters the column and an outlet through which blood exits the column and said inlet and outlet are arranged such that blood entering through the inlet is brought into contact with said heparinized solid substrate before it exits the column through the outlet.

17. The device according to claim 16, suitable for a blood flow rate of 2,000-7,000 mL/min.

18. The device according to claim 16, suitable for a blood flow rate of 200-500 mL/min.

19. The device according to claim 16, suitable for a blood How rate of 1-100 mL/min.

20. A method for extracorporeal removal of a harmful agent having a binding affinity to heparin from mammalian blood, comprising the steps:

a) providing a sample of mammalian blood,

b) bringing said sample into contact with the device of claim 1, under conditions allowing binding of said harmful agent to the heparin,

c) separating the sample from the solid substrate, such that said harmful agent is at least partially retained on the solid substrate, and

d) recovering said sample containing a reduced amount of said harmful agent.

21. The method according to claim 20, wherein said harmful agent is a pro-inflammatory cytokine.

22. A method for treatment of a mammalian subject suffering from a condition caused or aggravated by a harmful agent having a binding affinity to heparin, comprising the steps:

a) extracting blood from the subject,

b) bringing the extracted blood into contact with the device of claim 1, under conditions allowing binding of said harmful agent to the heparin,

c) reintroducing the blood, containing a reduced amount of said harmful agent, into the bloodstream of the subject.

23. An apparatus for extracorporeal circulation of blood or blood components, comprising a second extracorporeal blood treatment device in addition to the device of claim 1.

24. The apparatus according to claim 23, wherein said device of claim 1 is arranged downstream of the second extracorporeal blood treatment device.

25. The apparatus according to claim 23, wherein a surface concentration of said heparin of the device of claim 1 is 1-20 μ

g/cm².

26. The apparatus according to claim 23, wherein said second extracorporeal blood treatment device is a device for hemodialysis.

27. The apparatus according to claim 23, wherein said second extracorporeal blood treatment device is a device for oxygenation of blood.

28. A process for forming a covalent end point attachment of a full length heparin to a solid substrate comprising the steps of:

a) providing a solid substrate having primary amino functional groups,

b) mixing said solid substrate of a) with said full length heparin and a reducing agent in an aqueous medium,

c) allowing said full length heparin to bind covalently to the amino functional groups, wherein the covalent binding reaction between said full length heparin and the amino groups is performed at 60°

C., and

d) recovering the solid substrate having said full length heparin covalently bound on its surface.

29. The process according to claim 28, wherein a concentration of said full length heparin is in the range of 20-50 g/L.

30. The process according to claim 28, wherein the reducing agent is NaBH₃CN.

31. The process according to claim 28, wherein a pH-value of the aqueous medium of step b) is in the range of 3-5.

32. The process according to claim 28, further comprising a step of a second addition of NaBH₃CN during the covalent binding of step c).